Skip to main content
. 2021 Nov 1;32(11):971–978. doi: 10.5152/tjg.2020.20775

Table 1.

Comparison Baseline Characteristics Between RAP and Non-RAP Groups

Baseline Variables Non-RAP (n = 671) RAP (n = 163) P
Age (years) 48.00 ± 14.96 40.27 ± 10.00 <.001
Sex <.001
Male (n, %) 450 (67.06) 132 (80.98)
Female (n, %) 221 (32.94) 31 (19.02)
Smoking (n, %) 197 (29.35) 45 (27.6) .618
BMI (kg/m2) 24.68 ± 3.96 26.33 ± 4.29 <.001
Etiologies (n, %)
 Cholelithiasis 168 (25.04) 9 (5.52) <.001
 Alcohol 149 (22.21) 33 (20.25) .583
 Hypertriglyceridemia 244 (36.36) 105 (64.42) <.001
Comorbidities (n, %)
 Diabetes 97 (14.46) 37 (22.70) .010
 Hypertension 124 (18.48) 26 (15.95) .451
 Coronary heart disease 27 (4.02) 3 (1.84) .179
 History of biliary surgery 64 (9.54) 1 (0.61) <.001
Laboratory variables
 White blood cell count (×109/L) 12.89 (7.38-18.4) 12.48 (5.61-19.35) .417
 Platelet (×109/L) 207.8 (151.13-262.3) 218 (155.1-280.9) .153
 APTT (s) 28.36 (22.65-34.07) 27.5 (21.05-33.95) .220
 Fbg (mg/dL) 3.3 (2.15-4.45) 3.4 (2.09-4.71) .355
 BUN (mmol/L) 5.33 (1.9-9.61) 5.15 (2-11.03) .219
 Creatinine (µmmol/L) 74.45 (34.75-114.15) 71.8 (32.6-111) .743
 Amylase (U/L) 1250 (390-1650) 1145 (450-1705) .150
 Glycosylated hemoglobin 7.21 ± 2.38 7.43 ± 2.11 .627
 Blood glucose (mmol/L) 7.8 (6.6-9.9) 10.15 (7.47-12.83) .230
 TG (mmol/L) 4.27 (1.39-16) 15.52 (6-25.18) <.001
 HDL (mmol/L) 0.98 (0.66-1.33) 0.69 (0.53-0.87) <.001
 LDL (mmol/L) 2.17 (1.47-2.94) 1.85 (1.13-2.84) .051
 Cholesterol (mmol/L) 5.73 (4.72-8.26) 7.63 (5.64-10.76) <.001
Scoring system
 BISAP 1 (0-1) 1 (0-2) .105
 SOFA 0 (0-0.75) 0 (0-1) .565
Management (n, %)
 Lipid-lowering therapy 244 (36.36%) 105 (64.42%) <.001
 Cholecystectomy 33 (4.92%) 7 (4.29%) .102
Clinical outcomes
 ICU admission (n, %) 58 (8.64) 15 (9.2) .113
 LOS in hospital (day) 6 (5-9) 7 (5-10) .004

RAP, recurrent acute pancreatitis; BMI, body mass index; APTT, activated partial thromboplastin time; Fbg, fibrinogen; BUN, blood urea nitrogen; TG, triglyceride; HDL, high-density lipoprotein; LDL, low-density lipoprotein; SOFA, sequential organ failure assessment; BISAP, bedside index of severity in acute pancreatitis; LOS, length of stay.